OUP (Osage University Partners)
OUP is a venture capital fund investing in start-ups that commercialize university research.
Business Model: Education
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed OUP (Osage University Partners) Information
Geographic Data
Address: 50 Monument Road
City: Bala Cynwyd
State: CA
Zip: 19004
Country: US
Financial Info
Stage:
Raised Last:
$0
Raised Total:$350M
Social
Facebook
Twitter
Linkedin
Crunchbase
Metrics
4,859,126Website Global Rank
1,766Website Monthly Traffic
Twitter Followers
Description
Osage University Partners is a venture capital firm focused on investing in startups that are commercializing university technologies. Osage partners with research universities to invest in their innovative startups shareing its investment profit with partner institutions. The firm invests in software, hardware, and life science companies at all stages of company development. To date, it has partnered with over 80 universities, including 36 of the top 50 U.S. institutions by research expenditures, and has invested in over 50 of their spinouts.
Contact Phone:
+14844342255
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 6/2020 | StreetLight Data | Series D | 15M |
| 8/2019 | Landos Biopharma | Series B | 60M |
| 10/2013 | Immune Design | Series C | 49M |
| 6/2017 | Vector Launch | Series A | 0 |
| 9/2011 | Clinipace | Series C | 15M |
| 3/2017 | Antiva Biosciences | Series C | 22M |
| 12/2008 | Luxtera | Series D | 0 |
| 11/2012 | Tangent Medical Technologies | Series B | 8.6M |
| 10/2017 | Everactive | Venture Round | 40.3M |
| 7/2015 | Voxel8 | Series A | 12M |
| 10/2022 | Normunity | Series A | 65M |
| 11/2011 | Sera Prognostics | Series A | 19.3M |
| 3/2020 | ReCode Therapeutics | Series A | 0 |
| 8/2012 | Millendo Therapeutics | Series A | 16M |
| 2/2014 | Guardant Health | Series A | 10M |
| 12/2015 | Enlibrium | Series A | 15M |
| 6/2017 | Algorithmia | Series A | 10.5M |
| 12/2015 | Ribon Therapeutics | Venture Round | 10M |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 2/2016 | Ribon Therapeutics | Series A | 24M |
| 7/2021 | Verve Motion | Series A | 15M |
| 1/2019 | Seismos | Venture Round | 0 |
| 12/2017 | Menlo Security | Series C | 40.3M |
| 9/2020 | ESCAPE Bio | Venture Round | 73M |
| 7/2017 | ESCAPE Bio | Series A | 63M |
| 8/2020 | Aerovate Therapeutics | Series A | 72.6M |
| 6/2015 | Menlo Security | Series B | 25M |
| 11/2012 | Applied Genetics Technologies Corporation | Series B | 0 |
| 4/2019 | Satsuma Pharmaceuticals | Series B | 0 |
| 2/2017 | Bristol Myers Squibb | Post-IPO Equity | 80M |
| 10/2009 | Kolltan Pharmaceuticals | Series A | 0 |
| 11/2014 | Paracosm | Seed Round | 3.3M |
| 8/2013 | Evolv Technology | Series A | 11.8M |
| 6/2011 | SolarBridge Technologies | Series C | 0 |
| 4/2019 | Arrakis Therapeutics | Series B | 75M |
| 12/2020 | Atsena Therapeutics | Series A | 0 |
| 5/2012 | SolarBridge Technologies | Series D | 25M |
| 3/2019 | Hyalex Orthopaedics | Series A | 17M |
| 7/2018 | Antiva Biosciences | Series C | 15M |
| 6/2019 | Artizan Biosciences | Series A | 0 |
| 3/2018 | Clinipace | Venture Round | 0 |
| 6/2018 | Iconic Therapeutics | Venture Round | 0 |
| 3/2013 | Receptos | Series B | 30M |
| 3/2021 | EGenesis | Series C | 0 |
| 9/2015 | Selecta Biosciences | Series E | 38M |
| 1/2023 | Opsys Tech | Series C | 0 |
| 10/2013 | Sideris Pharmaceuticals | Series A | 32M |
| 9/2020 | Escient Pharmaceuticals | Series B | 77.5M |
| 5/2019 | Twentyeight-Seven Therapeutics | Series A | 15M |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 12/2011 | Liquid Light | Series A | 5.5M |
| 3/2014 | Kolltan Pharmaceuticals | Series D | 60M |
| 6/2014 | Jibo | Seed Round | 5M |
| 11/2011 | Tangent Medical Technologies | Series A | 4.5M |
| 8/2021 | Sonoma BioTherapeutics | Series B | 0 |
| 11/2017 | Quantum Circuits | Series A | 18M |
| 8/2016 | Ambiq Micro | Series D | 9.4M |
| 6/2013 | Kymeta | Series C | 50M |
| 7/2010 | MC10 | Series A | 0 |
| 3/2021 | Artizan Biosciences | Series A | 0 |
| 5/2019 | LunaPBC | Venture Round | 4.6M |
| 7/2018 | StreetLight Data | Series C | 0 |
| 11/2009 | Virdante Pharmaceuticals | Series A | 30M |
| 5/2009 | Avid Radiopharmaceuticals | Series D | 0 |
| 6/2018 | Embodied | Series A | 22M |
| 10/2018 | Modis Therapeutics | Series A | 30M |
| 7/2017 | Perceptive Automata | Seed Round | 0 |
| 2/2012 | SkyTree, Inc. | Seed Round | 1.5M |
| 5/2018 | Escient Pharmaceuticals | Series A | 40M |
| 7/2008 | Immune Design | Series A | 18M |
| 2/2002 | Luxtera | Series A | 6.8M |
| 6/2010 | Corridor Pharmaceuticals | Series A | 0 |
| 10/2009 | Corridor Pharmaceuticals | Series A | 0 |
| 1/2021 | Dice Therapeutics | Series C | 80M |
| 12/2015 | Effector Therapeutics | Series B | 40M |
| 4/2014 | Otonomy | Series D | 49M |
| 6/2011 | MC10 | Series B | 0 |
| 4/2015 | Seismos | Series A | 4M |
| 6/2019 | SiFive | Series D | 65.4M |
| 1/2016 | Iconic Therapeutics | Series C | 40M |
| 5/2018 | Medisix Therapeutics | Series A | 20M |
| 9/2014 | Liquid Light | Series B | 15M |
| 7/2017 | Corelight | Series A | 9.2M |
| 7/2008 | Kolltan Pharmaceuticals | Series A | 0 |
| 11/2014 | Ambiq Micro | Series C | 15.6M |
| 1/2019 | Ribon Therapeutics | Series B | 65M |
| 8/2016 | Iconic Therapeutics | Series C | 10M |
| 7/2015 | Picwell | Series A | 4M |
| 12/2017 | Pionyr Immunotherapeutics | Series B | 0 |
| 8/2018 | MC10 | Venture Round | 0 |
| 2/2021 | Cyteir Therapeutics | Series C | 0 |
| 8/2020 | SiFive | Series E | 0 |
| 2/2017 | Arrakis Therapeutics | Series A | 38M |
| 5/2017 | SiFive | Series B | 8.5M |
| 7/2010 | Immune Design | Series B | 32M |
| 11/2014 | Everactive | Series A | 5.3M |
| 8/2018 | Millendo Therapeutics | Venture Round | 30M |
| 1/2016 | Millendo Therapeutics | Series B | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 7/2017 | Effector Therapeutics | Series C | 38.6M |
| 8/2014 | Algorithmia | Seed Round | 2.6M |
| 10/2019 | ArsenalBio | Series A | 0 |
| 6/2016 | Cell Design Labs | Equity | 34.4M |
| 6/2016 | Blade Therapeutics | Series B | 45M |
| 3/2018 | Dracen Pharmaceuticals | Series A | 40M |
| 6/2021 | Ribon Therapeutics | Series C | 0 |
| 11/2019 | PMV Pharmaceuticals | Series C | 0 |
| 9/2016 | Fortis Therapeutics | Series A | 18M |
| 3/2021 | Fortis Therapeutics | Series A | 0 |
| 7/2017 | IonQ | Series A | 20M |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 3/2023 | Chroma Medicine | Series B | 0 |
| 10/2022 | Metalenz | Series B | 0 |
| 7/2015 | Blade Therapeutics | Series A | 6.5M |
| 5/2019 | Algorithmia | Series B | 25M |
| 3/2011 | Aerie Pharmaceuticals | Series B | 41.4M |
| 1/2016 | Kymeta | Series D | 62M |
| 8/2005 | Gevo | Series A | 500k |
| 9/2017 | Selecta Biosciences | Post-IPO Equity | 21M |
| 7/2018 | Spero Therapeutics | Post-IPO Equity | 75M |
| 7/2018 | Infinite Uptime | Series A | 5M |
| 10/2018 | Vector Launch | Series B | 0 |
| 9/2020 | Palladio Biosciences | Series B | 20M |
| 5/2015 | Precision BioSciences | Series A | 0 |
| 1/2017 | KenSci | Series A | 8.5M |
| 12/2018 | Elementary Robotics | Seed Round | 0 |
| 12/2012 | MC10 | Series C | 10M |
| 2/2019 | Vor Biopharma | Series A | 42M |
| 6/2023 | Kate Therapeutics | Series A | 0 |
| 10/2019 | Cyteir Therapeutics | Series B | 40.2M |
| 5/2021 | Interius BioTherapeutics | Series A | 0 |
| 3/2016 | Capella BioScience | Series A | 15.5M |
| 1/2023 | Hack The Box | Series B | 0 |
| 4/2018 | Synthorx | Series C | 63M |
| 3/2016 | StreetLight Data | Series B | 10M |
| 7/2020 | Vor Biopharma | Series B | 0 |
| 1/2006 | Avid Radiopharmaceuticals | Series A | 0 |
| 10/2012 | Mirna Therapeutics | Series C | 34.5M |
| 12/2013 | Infinio | Series B | 12M |
| 4/2018 | SiFive | Series C | 50.6M |
| 2/2019 | KenSci | Series B | 22M |
| 5/2017 | Hyalex Orthopaedics | Series A | 16M |
| 1/2021 | Coho Therapeutics | Seed Round | - |
| 1/2021 | Delfi Diagnostics | Series A | 0 |
| 10/2012 | Clinipace | Series C | 9M |
| 8/2020 | Censys | Series A | 15.5M |
| 10/2019 | IonQ | Series B | 55M |
| 3/2017 | Spero Therapeutics | Series C | 51.7M |
| 12/2015 | Everactive | Series B | 16.5M |
| 6/2022 | MicroTransponder | Series E | 0 |
| 11/2016 | Biohaven Pharmaceutical | Venture Round | 80M |
| 11/2012 | Cardioxyl Pharmaceuticals | Series B | 28M |
| 4/2018 | NuMat Technologies | Series B | 0 |
| 9/2021 | Corelight | Series D | 0 |
| 5/2016 | Aptinyx | Series A | 0 |
| 7/2019 | Menlo Security | Series D | 75M |
| 11/2020 | Menlo Security | Series E | 100M |
| 7/2021 | Glyphic Biotechnologies | Seed | 6M |
| 11/2014 | Menlo Security | Series A | 10.5M |
| 6/2022 | Nikola Labs | Series A | 0 |
| 3/2015 | Kura Oncology | Private Equity Round | 60M |
| 7/2014 | Faraday Pharmaceuticals | Series A | - |
| 9/2021 | Vanqua Bio | Series B | 85M |
| 3/2018 | Cyteir Therapeutics | Series B | 29M |
| 1/2011 | Tangent Medical Technologies | Seed Round | 2.5M |
| 11/2015 | Body Labs | Series A | 0 |
| 8/2021 | Dice Therapeutics | Series C | 60M |
| 11/2022 | Escient Pharmaceuticals | Series C | 120M |
| 4/2015 | Mirna Therapeutics | Series D | 0 |
| 6/2018 | Ambiq Micro | Venture Round | 0 |
| 4/2020 | Atsena Therapeutics | Venture Round | 8.2M |
| 1/2021 | Neuros Medical | Series B | 0 |
| 3/2022 | Brimstone Energy | Series A | 0 |
| 7/2018 | Seismos | Venture Round | 0 |
| 2/2017 | PMV Pharmaceuticals | Series B | 74M |
| 6/2012 | Tangent Medical Technologies | Venture Round | 7.9M |
| 5/2010 | Gevo | Series D | 0 |
| 3/2015 | Paracosm | Venture Round | 812k |
| 8/2017 | Neuros Medical | Series A | 20M |
| 9/2020 | Nido Biosciences | Venture Round | 18.4M |
| 8/2009 | Gevo | Venture Round | 0 |
| 12/2017 | Aptinyx | Series B | 70M |
| 8/2017 | Homology Medicines | Series B | 83.5M |
| 5/2018 | Beam Therapeutics | Series A | 87M |
| 5/2019 | LunaDNA | Venture Round | 4.6M |
| 9/2015 | Faraday Pharmaceuticals | Series A | 30M |
| 3/2012 | Receptos | Venture Round | 30M |
| 2/2015 | Merganser Biotech | Series A | 28M |
| 2/2018 | CounterFlow | Seed Round | 0 |
| 2/2016 | Spero Therapeutics | Series B | 30M |
| 4/2015 | Clarifai | Series A | 10M |
| 4/2021 | Hack The Box | Series A | 0 |
| 6/2018 | Precision BioSciences | Series B | 0 |
| 12/2014 | PMV Pharmaceuticals | Series A | 30M |
| 8/2016 | Cleave Therapeutics | Series B | 0 |
| 1/2014 | Menlo Security | Seed Round | - |
| 7/2017 | Lastline | Series C | 0 |
| 9/2013 | Otonomy | Series C | 45.9M |
| 11/2011 | Cleave Therapeutics | Series A | 42M |
| 1/2017 | Pionyr Immunotherapeutics | Series A | 8M |
| 10/2020 | Q32 Bio | Series B | 60M |
| 2/2018 | Picwell | Series B | 0 |
| 12/2016 | Merganser Biotech | Venture Round | - |
| 8/2019 | Cleave Therapeutics | Series C | 0 |
| 4/2013 | SkyTree, Inc. | Series A | 18M |
| 5/2013 | Effector Therapeutics | Series A | 45M |
| 7/2022 | Delfi Diagnostics | Series B | 0 |
| 6/2022 | Nikola Labs | Series A | 0 |
| 6/2022 | MicroTransponder | Series E | 0 |
| 3/2022 | Brimstone Energy | Series A | 0 |
| 11/2021 | Antiva Biosciences | Series D | 0 |
| 10/2021 | ReCode Therapeutics | Series B | 0 |
| 9/2021 | Vanqua Bio | Series B | 0 |
| 9/2021 | Corelight | Series D | 0 |
| 8/2021 | Effector Therapeutics | Post-IPO Equity | 0 |
| 8/2021 | Dice Therapeutics | Series C | 0 |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
